# Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

> **NCT01326481** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** TRC105
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01326481
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326481, "Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01326481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*